Clinical Trials Logo

Cannabis Hyperemesis Syndrome clinical trials

View clinical trials related to Cannabis Hyperemesis Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT05244460 Recruiting - Clinical trials for Cannabis Hyperemesis Syndrome

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

DOPE
Start date: December 2, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

NCT ID: NCT04176055 Completed - Clinical trials for Cannabis Hyperemesis Syndrome

Treatment Strategies in CHS

HALO
Start date: October 13, 2020
Phase: Phase 4
Study type: Interventional

Background: In the gastrointestinal (GI) system, the most well-described manifestation of prolonged cannabis use is cannabinoid hyperemesis syndrome (CHS). CHS is characterized by severe cyclic nausea and vomiting and associated with abdominal pain.Currently, the generally accepted management for CHS is complete cannabis abstinence as traditional anti-emetics appear to be minimally effective. Preliminary reports from emergency departments suggest that intravenous haloperidol, a typical anti- psychotic, provides effective symptomatic relief in CHS. Objective: 1. To learn more about how cannabis use relates to the management of CHS. 2. To learn if haloperidol is effective in treating the symptoms of CHS. Eligibility: Alberta residents with ongoing cannabis use, who have completed the baseline study, are ≥ 18 years and ≤ 65 years, and have gastrointestinal symptomology as measured by GCSI > 2 or PAGI-SYM > 2 (upper or lower abdominal pain subscale). Design: Participants will answer a series of questionnaires online. Study specific questions relating to symptoms, cannabis use, and anxiety and depression will be administered. Confirmation of cannabis cessation will be assessed with urine creatinine and cannabis metabolite measures. Salivary cortisol will be used to asses the stress response.